- Evotec SE (EVO, Financial) reports a 2% revenue increase to €797.0 million for FY 2024, with Q4 revenues up 10% to €221.2 million.
- The Just - Evotec Biologics segment grew 71% year-over-year, contributing €185.6 million to overall revenue.
- 2025 guidance projects revenues between €840-880 million, with an adjusted EBITDA of €30-50 million.
Evotec SE (EVO) has announced its financial results for the fiscal year 2024, showcasing a 2% rise in total revenues, reaching €797.0 million. The company reported a notable 10% increase in Q4 2024 revenues, amounting to €221.2 million, indicating potential business acceleration.
The highlight of the fiscal year was the impressive performance of the Just - Evotec Biologics segment, which saw a 71% year-over-year growth, contributing €185.6 million to the overall topline. However, the Shared R&D revenues declined by 9% to €611.4 million, affected by temporary pharmaceutical restructuring and selective biotech funding.
Evotec's Priority Reset program is on track to deliver €40 million in annual savings, improving the net debt leverage ratio to 1.9x. The company has secured key partnerships with pharmaceutical giants like Bristol Myers Squibb, Novo Nordisk, and Pfizer, validating its technology platform.
Looking ahead to 2025, Evotec projects a revenue range of €840-880 million, reflecting a growth rate of 5-10%, and anticipates an adjusted Group EBITDA of €30-50 million. The company's 2028 outlook targets a revenue CAGR of 8-12% and an adjusted EBITDA margin above 20%, as it continues to focus on pioneering drug discovery and biologics.
